Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Lunac Therapeutics Ltd.. (11/14/19). "Press Release: Lunac Therapeutics Spun Out to Develop Next Generation Anticoagulants, and Announces Series A Funding Round". Leeds.

Region Region Leeds, West Yorkshire
  Country United Kingdom (GB)
Organisations Organisation Lunac Therapeutics Ltd.
  Organisation 2 Epidarex Capital (Group)
Products Product anticoagulant
  Product 2 venture capital
Index terms Index term Lunac Therapeutics–SEVERAL: investment, 201911 financing round Series A first closing £2.65m co-led by Epidarex Capital + Univ Leeds
  Index term 2 Lunac Therapeutics–Univ Leeds: investment, 201911 financing round Series A first closing totalling £2.65m incl co-lead investor Univ Leeds
Persons Person Canning, Mary (Epidarex Capital 201911)
  Person 2 Duley, Andy (Univ Leeds 201911 Director of Commercialisation)
     


> Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII

> Builds on a decade of academic research into Factor XII

> Investment round led by Epidarex Capital and University of Leeds


LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced it has spun out of the University of Leeds with £2.65M funding in the first close of a Series A financing round. The investment is being led by Epidarex Capital and the University of Leeds. The Company was founded based on IP generated by Prof Helen Philippou and Dr Richard Foster, through unique insights built on a decade of academic research into Factor XII which has been supported by the Wellcome Trust, British Heart Foundation and the Medical Research Council.

LUNAC is targeting activated Factor XII to identify and develop next-generation anticoagulants. Current therapies carry the risk of causing bleeding, and LUNAC believes that targeting the coagulation cascade at the level of Factor XII will reduce this risk. Factor XII is implicated in the formation of pathological clot formation, but not the stemming of bleeding. Furthermore, individuals who lack Factor XII do not exhibit bleeding symptoms, unlike those with a deficiency of any other coagulation factor.

Prof Helen Philippou, Scientific Founder of LUNAC Therapeutics, said: “There is an urgent need for anticoagulant therapies with reduced bleeding risk. Our research has validated that targeting activated Factor XII may lead to differentiated therapies and a new treatment option for patients.”

Dr Mary Canning of Epidarex Capital, added: “LUNAC is taking a unique approach to the identification of novel anticoagulants, and we have been very impressed by the progress of the Factor XII program at the University of Leeds. This investment builds on Epidarex’s track record of funding innovative spin-outs from leading research universities, both across the UK and in the US.”

Andy Duley, Director of Commercialisation at the University of Leeds, commented: “We are excited to be working together with Epidarex Capital on this significant funding round, to maximise the potential of the University’s research in the field of anticoagulation and build upon the decade of academic research into Factor XII at the University.”


Contacts

Lorna Cuddon
Zyme Communications
Tel: +44(0)7811996942
Email: lorna.cuddon@zymecommunications.com

   
Record changed: 2020-01-04

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

More documents for Lunac Therapeutics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top